NEW YORK, Feb 10, 2026, 11:13 a.m. EST — Regular session trading
- In midday action, Inspire Medical Systems shares jumped roughly 6%, breaking a two-day stretch of drifting.
- The sleep-apnea device maker is set to release both its fourth-quarter and full-year numbers following the close on Wednesday.
- After last month’s preliminary revenue and guidance, traders are looking ahead to what the company will say about its 2026 outlook.
Inspire Medical Systems jumped 6.2% Tuesday to close at $70.44, handily outstripping the broader market’s choppy action ahead of its earnings release slated for this day. Shares touched $71.15 during the session, though still sit roughly 64% under their 52-week high.
This matters: Wednesday’s report is shaping up as a key near-term milestone for a stock that’s been tossed around by shifting expectations on reimbursement and procedure growth. The shares remain well below last year’s highs, so even subtle tweaks in guidance language could have an outsized impact.
Inspire plans to report its fourth-quarter and full-year 2025 results following the market close on Wednesday, Feb. 11. The company is scheduling a conference call for 5:00 p.m. Eastern that day.
The company markets an implanted neurostimulation treatment targeting obstructive sleep apnea, a disorder that disrupts breathing during sleep and often leaves people persistently fatigued, with increased health risks down the line.
Back in January, Inspire rolled out its early, unaudited revenue numbers for both the quarter and the full year, and also set out its first revenue target for 2026. CEO Tim Herbert called the fourth quarter’s results “very pleased,” saying the year wrapped up with “significant momentum.” GlobeNewswire
The move higher on Tuesday wasn’t about any new headlines from the company. Instead, investors seemed to be jockeying ahead of the results, trying to gauge if the final audited figures will come in close to those early estimates — and if there’s any change to the 2026 outlook.
The main thing to watch on the call: implant volume cadence. Reimbursement and coding snags—any remarks there could move the needle. Management’s tone about early 2026, whether they’re signaling speed-up or pumping the brakes, will be key. Investors want specifics on profitability and how operating costs are shaping up as the company ramps.
But here’s the snag: those January numbers are both preliminary and unaudited, with the company flagging that they might shift after the books close and auditors get involved. Investors already watching the stock slide from its highs got another reminder—unexpected tweaks, even minor ones, can sting.
Traders aren’t likely to chase Tuesday’s rally much further. They’ll be watching for Wednesday’s earnings after the close, then tuning in at 5 p.m. ET, where early questions will almost certainly target 2026 demand and whether growth can stick.
